Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

The aims of the present study were to establish the maximally tolerated dose (MTD) of the histone deacetylase inhibitor valproate together with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with diffuse large B-cell lymphoma (DLBCL). A phase 1 dose escala...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood Adv
Huvudupphovsmän: Drott, Kristina, Hagberg, Hans, Papworth, Karin, Relander, Thomas, Jerkeman, Mats
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2018
Ämnen:
Lymphoid Neoplasia
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6020808/
https://ncbi.nlm.nih.gov/pubmed/29903707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019240
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk